{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:28:31Z","timestamp":1793212111447,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd007572.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2016,11,25]],"date-time":"2016-11-25T00:00:00Z","timestamp":1480032000000}}],"reference-count":78,"publisher":"Wiley","issue":"11","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd007572.pub3","type":"journal-article","created":{"date-parts":[[2016,11,25]],"date-time":"2016-11-25T04:22:09Z","timestamp":1480047729000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Anti-IL-12\/23p40 antibodies for induction of remission in Crohn's disease"],"prefix":"10.1002","volume":"2016","author":[{"given":"John K","family":"MacDonald","sequence":"first","affiliation":[{"name":"Robarts Clinical Trials; Cochrane IBD Group; 100 Dundas Street, Suite 200 London ON Canada N6A 5B6"},{"name":"University of Western Ontario; Department of Medicine; London ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tran M","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Robarts Clinical Trials; Cochrane IBD Group; 100 Dundas Street, Suite 200 London ON Canada N6A 5B6"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reena","family":"Khanna","sequence":"additional","affiliation":[{"name":"University of Western Ontario; Department of Medicine; London ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antje","family":"Timmer","sequence":"additional","affiliation":[{"name":"Carl von Ossietzky University of Oldenburg; Department of Health Services Research; Oldenburg Germany 26111"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,11,25]]},"reference":[{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD007572.pub3-BIB0001|cit1","first-page":"S408","article-title":"Pharmacokinetics and exposure-response relationships of ustekinumab during IV induction and SC maintenance treatment of patients with Crohn's disease with ustekinumab: Results from the UNITI-1, UNITI-2, and IM-UNITI studies","volume":"150","author":"Adedokun","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD007572.pub3-BIB0002|cit2","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn's disease","author":"Feagan","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD007572.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"S377","DOI":"10.1016\/S0016-5085(16)31326-9","article-title":"Molecular response to ustekinumab in moderate-to-severe Crohn's disease by serum protein analysis: Results from uniti-1 induction, uniti-2 induction, and imuniti maintenance studies","volume":"150","author":"Li","year":"2016","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD007572.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/MIB.0000000000000720","article-title":"A multicenter, double-blind, placebo-controlled phase 3 study of ustekinumab, a human IL-12\/23P40 mAB, in moderate to severe Crohn's disease refractory to anti-TFNalpha: UNITI-1","volume":"22","author":"Sandborn","year":"2016","journal-title":"Inflammatory Bowel Diseases"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD007572.pub3-BIB0005|cit5","first-page":"S982","article-title":"Assessment of serum C-reactive protein, fecal lactoferrin, and fecal calprotectin in patients with moderate-severely active Crohns disease: Results from the IM UNITI maintenance study","volume":"150","author":"Sandborn","year":"2016","journal-title":"Gastroenterology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD007572.pub3-BIB0006|cit6","first-page":"S1004","article-title":"Ustekinumab improves general health status and disease-specific health related quality of life of patients with moderate to severe Crohn's disease: Results from the uniti and IMUNITI phase 3 clinical trials","volume":"150","author":"Sands","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD007572.pub3-BIB0007|cit7","article-title":"A multicenter, double-blind, placebo-controlled pH3 study of ustekinumab, a human monoclonal antibody to IL-12\/23p40, in patients with moderately-severely active Crohn's disease who are not naive or not refractory to anti-TNFa: UNITI-2","volume":"2016","author":"Feagan","year":"2016","journal-title":"Canadian Journal of Gastroenterology and Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD007572.pub3-BIB0008|cit8","first-page":"563","article-title":"A multicenter, double-blind, placebo-controlled pH3 study of ustekinumab, a human monoclonal antibody to IL-12\/23p40, in patients with moderately-severely active Crohn's disease who are not naive or not refractory to anti-TNFa: UNITI-2","volume":"3","author":"Feagan","year":"2015","journal-title":"United European Gastroenterology Journal"},{"issue":"4 Suppl 2","key":"10.1002\/14651858.CD007572.pub3-BIB0009|cit9","first-page":"A22","article-title":"Anti-interleukin-12 treats active Crohn's disease","volume":"126","author":"Mannon","year":"2004","journal-title":"Gastroenterology"},{"issue":"20","key":"10.1002\/14651858.CD007572.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1056\/NEJMoa033402","article-title":"Anti-interleukin-12 antibody for active Crohn's disease","volume":"351","author":"Mannon","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"Supp 1","key":"10.1002\/14651858.CD007572.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"S457","DOI":"10.14309\/00000434-201010001-01245","article-title":"Briakinumab (anti-interleukin 12\/23p40, ABT874) for treatment of Crohn's disease","volume":"105","author":"Panaccione","year":"2010","journal-title":"American Journal of Gastroenterology"},{"issue":"6","key":"10.1002\/14651858.CD007572.pub3-BIB0012|cit12","first-page":"1329","article-title":"Briakinumab for treatment of Crohn's disease: results of a randomized trial","volume":"21","author":"Panaccione","year":"2015","journal-title":"Inflammatory Bowel Diseases"},{"issue":"Supp 1","key":"10.1002\/14651858.CD007572.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1097\/00054725-200802001-00032","article-title":"A multicenter, randomized, phase 2A study of human monoclonal antibody to IL- 12\/23P40 (CNTO 1275) in patients with moderately to severely active Crohn\u2019s disease","volume":"14","author":"Sandborn","year":"2008","journal-title":"Inflammatory Bowel Diseases"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD007572.pub3-BIB0014|cit14","first-page":"A51","article-title":"A multicenter, randomized, phase 2a study of human monoclonal antibody to IL-12\/23p40 (CNTO 1275) in patients with moderately to severely active Crohn's disease","volume":"132","author":"Sandborn","year":"2007","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD007572.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1053\/j.gastro.2008.07.014","article-title":"A randomized trial of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease","volume":"135","author":"Sandborn","year":"2008","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1002\/14651858.CD007572.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1038\/ajg.2009.454","article-title":"Relationship of C-reactive protein with clinical response after therapy with ustekinumab in Crohn's disease","volume":"104","author":"Toedter","year":"2009","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD007572.pub3-BIB0017|cit17","volume":"2016","author":"Ding","year":"2016","journal-title":"Canadian Journal of Gastroenterology and Hepatology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD007572.pub3-BIB0019|cit18","doi-asserted-by":"crossref","first-page":"S713","DOI":"10.1016\/S0016-5085(15)32426-4","volume":"148","author":"Ding","year":"2015","journal-title":"Gastroenterology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD007572.pub3-BIB0018|cit19","first-page":"A133","volume":"3","author":"Ding","year":"2015","journal-title":"United European Gastroenterology Journal"},{"issue":"Supp 2s","key":"10.1002\/14651858.CD007572.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"S463","DOI":"10.14309\/00000434-201110002-01227","article-title":"A multicenter, randomized, double-blind, placebo-controlled phase 2B study of ustekinumab, a human monoclonal antibody to IL-12\/23P40, in patients with moderately to severely active Crohn's disease: Results through week 36 from the CERTIFI trial","volume":"106","author":"Feagan","year":"2011","journal-title":"American Journal of Gastroenterology"},{"issue":"Supp 1","key":"10.1002\/14651858.CD007572.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.1016\/S1873-9946(12)60320-1","article-title":"Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double-blind, placebo-controlled Phase2b study of ustekinumab in patients with moderately to severely active Crohn's disease","volume":"6","author":"Feagan","year":"2012","journal-title":"Journal of Crohn's and Colitis"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD007572.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"S231","DOI":"10.1016\/S0016-5085(13)60817-3","article-title":"Assessment of sleep impairment in patients with Crohn's disease: Results from the ustekinumab CERTIFI study","volume":"144","author":"Gasink","year":"2013","journal-title":"Gastroenterology"},{"issue":"Suppl 2s","key":"10.1002\/14651858.CD007572.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"S497","DOI":"10.14309\/00000434-201410002-01679","article-title":"Evaluation of an interim Crohn's disease outcome measure (PRO-2) based on 2 patient-reported components (stool frequency, abdominal pain) of the Crohn's disease activity index (CDAI) in the ustekinumab CERTIFI study","volume":"109","author":"Gasink","year":"2014","journal-title":"American Journal of Gastroenterology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD007572.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1016\/S0016-5085(11)60443-5","article-title":"A multicenter, randomized, double-blind, placebo-controlled Phase2b study of ustekinumab, a human monoclonal antibody to IL-12\/23p40, in patients with moderately to severely active Crohn's disease: Results through week 22 from the CERTIFI trial","volume":"140","author":"Sandborn","year":"2011","journal-title":"Gastroenterology"},{"issue":"16","key":"10.1002\/14651858.CD007572.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","article-title":"Ustekinumab induction and maintenance therapy in refractory Crohn's disease","volume":"367","author":"Sandborn","year":"2012","journal-title":"New England Journal of Medicine"},{"issue":"Supp 2","key":"10.1002\/14651858.CD007572.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1097\/00054725-201112002-00076","article-title":"Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double-blind, placebo-controlled phase2b study ofUstekinumab in patients with moderately to severely active Crohn's disease","volume":"17","author":"Sands","year":"2011","journal-title":"Inflammatory Bowel Diseases"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD007572.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"S264","DOI":"10.1016\/S0016-5085(11)61056-1","article-title":"Reductions in fecal calprotectin and lactoferrin following ustekinumab induction therapy in patients with moderate to severe Crohn's disease who have previously failed or been intolerant of TNF antagonist therapies","volume":"140","author":"Toedter","year":"2011","journal-title":"Gastroenterology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD007572.pub3-BIB0028|cit28","first-page":"A","article-title":"Pharmacokinetics and exposure-response relationship of ustekinumab, a human monoclonal antibody to interleukin 12\/23 in patients with moderate-to-severe Crohn's disease","volume":"134","author":"Fasanmade","year":"2008","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1002\/14651858.CD007572.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1002\/ibd.21159","article-title":"Randomized, double-blind, placebo-controlled trial of the oral interleukin-12\/23 inhibitor apilimod mesylate for treatment of active Crohn's disease","volume":"16","author":"Sands","year":"2010","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1002\/14651858.CD007572.pub3-BIB0030|cit30","unstructured":"NCT01369329 A phase 3, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the safety and efficacy of ustekinumab induction therapy in subjects with moderately to severely active Crohn's disease who have failed or are intolerant to TNF antagonist therapy (UNITI-1) clinicaltrials.gov\/ct2\/show\/NCT01369329"},{"key":"10.1002\/14651858.CD007572.pub3-BIB0031|cit31","unstructured":"NCT01369342 A phase 3, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the safety and efficacy of ustekinumab induction therapy in subjects with moderately to severely active Crohn's disease (UNITI-2) clinicaltrials.gov\/ct2\/show\/NCT01369342"},{"key":"10.1002\/14651858.CD007572.pub3-BIB0032|cit32","unstructured":"NCT01369355 A phase 3, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the safety and efficacy of ustekinumab maintenance therapy in subjects with moderately to severely active Crohn's disease clinicaltrials.gov\/ct2\/show\/NCT01369355"},{"issue":"4","key":"10.1002\/14651858.CD007572.pub3-BIB0033|cit33","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003574.pub2","article-title":"Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease","author":"Akobeng","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD007572.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/nbt.1903","article-title":"Therapeutic targeting of the IL-12\/23 pathways: generation and characterization of ustekinumab","volume":"29","author":"Benson","year":"2011","journal-title":"Nature Biotechnology"},{"issue":"4","key":"10.1002\/14651858.CD007572.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/annrheumdis-2011-201244","article-title":"Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease","volume":"72","author":"Burmester","year":"2013","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"4","key":"10.1002\/14651858.CD007572.pub3-BIB0036|cit36","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000545.pub4","article-title":"Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease","author":"Chande","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD007572.pub3-BIB0037|cit37","first-page":"216","article-title":"Ustekinumab","volume":"1","author":"Cingoz","year":"2011","journal-title":"Monoclonal Antibodies"},{"issue":"1","key":"10.1002\/14651858.CD007572.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/j.gastro.2003.10.047","article-title":"The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients","volume":"126","author":"Colombel","year":"2004","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD007572.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"issue":"15","key":"10.1002\/14651858.CD007572.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn's disease","volume":"362","author":"Colombel","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD007572.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2036.2011.04679.x","article-title":"Review article: Causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF-\u03b1 therapy","volume":"34","author":"Danese","year":"2011","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"7","key":"10.1002\/14651858.CD007572.pub3-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3109\/07853890.2011.577093","article-title":"Interleukin-23: a key cytokine in inflammatory diseases","volume":"43","author":"Duvallet","year":"2011","journal-title":"Annals of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD007572.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1053\/gast.2001.26279","article-title":"The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study","volume":"121","author":"Faubion","year":"2001","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD007572.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/ajg.2011.70","article-title":"Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis","volume":"106","author":"Ford","year":"2011","journal-title":"American Journal of Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD007572.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/S0016-5085(99)70392-6","article-title":"Anti-interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice","volume":"117","author":"Fuss","year":"1999","journal-title":"Gastroenterology"},{"issue":"9664","key":"10.1002\/14651858.CD007572.pub3-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0140-6736(09)60140-9","article-title":"Ustekinumab, a human interleukin 12\/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial","volume":"373","author":"Gottlieb","year":"2009","journal-title":"Lancet"},{"issue":"12","key":"10.1002\/14651858.CD007572.pub3-BIB0047|cit47","first-page":"1441","article-title":"Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies","volume":"13","author":"Gottlieb","year":"2014","journal-title":"Journal of Drugs in Dermatology"},{"issue":"7650","key":"10.1002\/14651858.CD007572.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"9317","key":"10.1002\/14651858.CD007572.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD007572.pub3-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD007572.pub3-BIB0051|cit51","article-title":"Chapter 8: Assessing risk of bias in included studies","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)","author":"Higgins","year":"2011. Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD007572.pub3-BIB0052|cit52","article-title":"Chapter 16: Special topics in statistics","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)","author":"Higgins","year":"2011. Available from www.cochrane-handbook.org"},{"issue":"3","key":"10.1002\/14651858.CD007572.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1097\/MIB.0b013e318280ebbd","article-title":"Risk of extraintestinal solid cancer with anti-TNF therapy in adults with inflammatory bowel disease: review of the literature","volume":"19","author":"Hudesman","year":"2013","journal-title":"Inflammatory Bowel Diseases"},{"issue":"8","key":"10.1002\/14651858.CD007572.pub3-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2217\/imt.13.81","article-title":"Ustekinumab for the treatment of Crohn's disease","volume":"5","author":"Khanna","year":"2013","journal-title":"Immunotherapy"},{"issue":"3","key":"10.1002\/14651858.CD007572.pub3-BIB0055|cit55","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005112.pub2","article-title":"Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis","author":"Lawson","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD007572.pub3-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1471-2288-7-32","article-title":"Systematic reviews of adverse effects: framework for a structured approach","volume":"7","author":"Loke","year":"2007","journal-title":"BMC Medical Research Methodology"},{"issue":"12","key":"10.1002\/14651858.CD007572.pub3-BIB0057|cit57","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003459.pub3","article-title":"Methotrexate for induction of remission in refractory Crohn's disease","author":"McDonald","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD007572.pub3-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/0016-5085(90)90002-I","article-title":"Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Th\u00e9rapeutique des Affections Inflammatoires Digestives","volume":"98","author":"ModiglianiR","year":"1990","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD007572.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"46-54.e42; quiz","DOI":"10.1053\/j.gastro.2011.10.001","article-title":"Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review","volume":"142","author":"Molodecky","year":"2012","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD007572.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1084\/jem.182.5.1281","article-title":"Antibodies to interleukin 12 abrogate established experimental colitis in mice","volume":"182","author":"Neurath","year":"1995","journal-title":"Journal of Experimental Medicine"},{"issue":"12","key":"10.1002\/14651858.CD007572.pub3-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.2174\/13894501113146660229","article-title":"Anti-IL-12\/23 in Crohn's disease: bench and bedside","volume":"14","author":"Niederreiter","year":"2013","journal-title":"Current Drug Targets"},{"issue":"9625","key":"10.1002\/14651858.CD007572.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD007572.pub3-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/bjd.12214","article-title":"Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up.","volume":"168","author":"Papp","year":"2013","journal-title":"British Journal of Dermatology"},{"issue":"35","key":"10.1002\/14651858.CD007572.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"5606","DOI":"10.3748\/wjg.v12.i35.5606","article-title":"Interleukin-12 and Th1 immune response in Crohn's disease: pathogenetic relevance and therapeutic implication","volume":"12","author":"Peluso","year":"2006","journal-title":"World Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD007572.pub3-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1136\/fg.2009.000174","article-title":"Optimising use of thiopurines in inflammatory bowel disease","volume":"1","author":"Raj","year":"2010","journal-title":"Frontline Gastroenterology"},{"issue":"17","key":"10.1002\/14651858.CD007572.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1056\/NEJMoa1010858","article-title":"A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis","volume":"365","author":"Reich","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD007572.pub3-BIB0067|cit67","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2008"},{"issue":"13","key":"10.1002\/14651858.CD007572.pub3-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJM199409293311304","article-title":"A comparison of budesonide with prednisolone for active Crohn's disease","volume":"331","author":"Rutgeerts","year":"1994","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD007572.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa067594","article-title":"Certolizumab pegol for the treatment of Crohn's disease","volume":"357","author":"Sandborn","year":"2007","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD007572.pub3-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa062897","article-title":"Maintenance therapy with certolizumab pegol for Crohn's disease","volume":"357","author":"Schreiber","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD007572.pub3-BIB0071|cit71","article-title":"Chapter 12: Interpreting results and drawing conclusions","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)","author":"Sch\u00fcnemann","year":"2011. Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD007572.pub3-BIB0072|cit72","first-page":"CD008794","article-title":"Adverse effects of biologics: a network meta-analysis and Cochrane overview","volume":"2","author":"Singh","year":"2011","journal-title":"Cochrane database of systematic reviews"},{"issue":"12","key":"10.1002\/14651858.CD007572.pub3-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/j.mayocp.2014.08.019","article-title":"Comparative efficacy of biologic therapy in biologic-naive patients with Crohn disease: a systematic review and network meta-analysis","volume":"89","author":"Singh","year":"2014","journal-title":"Mayo Clinic Proceedings"},{"issue":"12","key":"10.1002\/14651858.CD007572.pub3-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/j.cgh.2007.09.002","article-title":"Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study","volume":"5","author":"Solberg","year":"2007","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"4 Part 2","key":"10.1002\/14651858.CD007572.pub3-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/0016-5085(79)90385-8","article-title":"National Cooperative Crohn's Disease Study: results of drug treatment","volume":"77","author":"Summers","year":"1979","journal-title":"Gastroenterology"},{"issue":"15","key":"10.1002\/14651858.CD007572.pub3-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.","volume":"337","author":"Targan","year":"1997","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD007572.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/ni1092","article-title":"NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses","volume":"5","author":"Watanabe","year":"2004","journal-title":"Nature Immunology"},{"issue":"4","key":"10.1002\/14651858.CD007572.pub3-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/j.1572-0241.2002.05596.x","article-title":"Corticosteroids in Crohn's disease","volume":"97","author":"Yang","year":"2002","journal-title":"American Journal of Gastroenterology"}],"updated-by":[{"DOI":"10.1002\/14651858.cd007572.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD007572.pub3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,8]],"date-time":"2024-09-08T12:23:01Z","timestamp":1725798181000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD007572.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane IBD Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,11,25]]},"references-count":78,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2016,11]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd007572.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,25]]}}}